What they are
Non-steroidal anti-inflammatory drugs (NSAIDs) are a heterogeneous class of agents that inhibit cyclooxygenases (COX), reducing prostaglandins involved in pain, inflammation, and fever. Although the name suggests uniformity, differences across molecules — potency, selectivity, half-life, and risk profile — are clinically meaningful and guide drug selection.
Non-selective agents inhibit COX-1 and COX-2 (ibuprofen, naproxen, ketoprofen, diclofenac); nimesulide has a particular profile (relative preference for COX-2, distinct hepatic signal). The coxibs (celecoxib, etoricoxib) better preserve gastric COX-1, lowering GI complications with a variable CV profile. Aspirin inhibits COX-1 irreversibly and is used mainly for cardioprotection, not as a routine analgesic.
COX inhibition
NSAIDs block cyclooxygenases and reduce inflammatory prostaglandins — different from acetaminophen and dipyrone, which act predominantly in the CNS.
Heterogeneous class
Efficacy is similar across molecules, but the risk profile (GI, CV, renal, hepatic) varies considerably — selection is individualized and guided by comorbidities.
Golden rule
Lowest effective dose for the shortest possible time. Even over-the-counter agents have meaningful adverse effects with prolonged use.
Mechanism of action
In the setting of tissue injury, local cells express COX-2 and produce prostaglandins (especially PGE2), which sensitize nociceptors and amplify inflammation. NSAIDs inhibit this cascade — less PGE2 means less sensitive nociceptors, less edema, and less hyperalgesia.
COX-1 is constitutive (it protects gastric mucosa, sustains platelet hemostasis and renal function); COX-2 is induced by inflammation. Non-selective agents inhibit both and therefore cause gastropathy and bleeding; coxibs relatively spare COX-1, lowering GI risk — but preferential inhibition of endothelial COX-2 shifts the prostacyclin/thromboxane balance and contributes to the cardiovascular signal observed with this class. There is also a modest central component, but what distinguishes NSAIDs from acetaminophen and dipyrone is the direct peripheral anti-inflammatory effect.
Pharmacologic Pathway of NSAIDs
Tissue injury and inflammation
Trauma, infection, or autoimmune processes activate phospholipases and release arachidonic acid from cell membranes.
COX-1 / COX-2 expression
COX-1 (constitutive — gastric protection, platelets, kidney) and COX-2 (induced — inflammation) convert arachidonic acid into prostaglandins.
NSAID inhibits COX
Non-selective agents (ibuprofen, naproxen, diclofenac) block both enzymes; coxibs (celecoxib, etoricoxib) predominantly inhibit COX-2.
Less PG, less pain and less inflammation
Lower PGE2 means fewer sensitized nociceptors and less edema — with the trade-off of adverse effects tied to COX inhibition.
Scientific evidence
The evidence on NSAIDs is among the most extensive in pain pharmacotherapy — and clearly separates acute inflammatory pain (consistent performance) from continuous use in chronic pain (efficacy persists, but risk dominates).
The network meta-analysis by da Costa et al. (Lancet 2017) compared NSAIDs in knee and hip OA (70+ trials, 58,000 patients): efficacy differences across molecules were small (high-dose diclofenac led), while the risk profile varies much more — the choice is largely a question of individualized safety. Cochrane reviews by drug show NNT for 50% relief around 2-3 in postoperative pain. In primary dysmenorrhea, NSAIDs are first-line; in tension headache and acute migraine, ibuprofen and naproxen have good evidence; in acute low back pain, they have a modest but reproducible effect — unlike acetaminophen, they retain superiority over placebo.
The PRECISION trial (Bhatt et al., NEJM 2016) compared celecoxib, naproxen, and ibuprofen in patients with arthritis and increased CV risk: celecoxib was non-inferior on major CV outcomes and had fewer GI and renal complications — recalibrating the perception of coxibs as "necessarily worse" on the CV axis. OARSI 2019 and NICE 2022 keep NSAIDs as a central piece in OA (preferring topicals when applicable) and emphasize the lowest dose for the shortest time, with gastric protection in higher-risk patients.
Indications
NSAIDs are indicated when the inflammatory component is prominent and the risk profile allows. The decision weighs indication, duration, and comorbidities — and rests with the physician.
Indications for NSAIDs
- 01
Acute musculoskeletal pain
Sprains, strains, tendinopathy in the inflammatory phase, acute low back pain. Short course, 5-10 days.
- 02
Primary dysmenorrhea
Established first-line — ibuprofen or naproxen, started at symptom onset, offer robust efficacy.
- 03
Tension headache and acute migraine
Ibuprofen 400-600 mg, naproxen 500-1000 mg, and high-dose aspirin have good evidence in mild-to-moderate attacks.
- 04
Osteoarthritis flare
Short course during exacerbations; prefer topical agents for superficial joints; limit prolonged oral use.
- 05
Postoperative pain (as part of multimodal analgesia)
They reduce opioid consumption (sparing effect) and are central in enhanced recovery protocols when not contraindicated.
- 06
Inflammatory rheumatologic diseases
RA, ankylosing spondylitis, and seronegative arthropathies — followed by rheumatology, as a bridge or adjunct to DMARDs/biologics.
How they are used
In Brazil, NSAIDs are available as tablets, capsules, drops, pediatric suspensions, injectables (ketoprofen/diclofenac IM/IV in hospital), and topical preparations. Oral onset of action is 30 to 60 minutes; dosing intervals depend on half-life (ibuprofen every 6-8 h, naproxen every 12 h, celecoxib and etoricoxib once daily). The golden rule is the lowest effective dose for the shortest possible time — 3-7 days with reassessment in acute pain; in prolonged use, reassess every 4-6 weeks with checks of blood pressure, renal function, GI symptoms, and consideration of alternatives (including non-pharmacologic options).
Clinical Approach to NSAID Use
Step 1
initial visitPain and comorbidity assessment
Characterize the pain (inflammatory component, duration, intensity) and assess CV, GI, renal, and hepatic risk.
Step 2
prescriptionChoose the NSAID with the best profile
GI risk: coxib + PPI. CV risk: avoid diclofenac and etoricoxib (naproxen is safer). Renal or HF risk: avoid oral if possible. Superficial joint: start with a topical.
Step 3
3-10 initial daysLowest effective dose, shortest possible time
Use initially for a defined period (3-10 days in acute pain), with counseling on GI symptoms, edema, blood pressure, and allergic reactions. Add a PPI in patients at higher GI risk.
Step 4
as response indicatesReassessment in days to weeks
If there is no improvement, reassess the diagnosis — do not escalate by default. If the patient improves, discontinue early. For chronic use, reassess every 4-6 weeks.
NSAIDs by generic name
Availability is wide, with established generics in most markets. Public health systems and insurance commonly cover ibuprofen, naproxen, and diclofenac; celecoxib and etoricoxib are typically out-of-pocket or insurance. Over the counter (varies by country): ibuprofen 200 mg and aspirin 500 mg — ibuprofen 400 mg often requires a prescription.
COMMONLY USED NSAIDS
| ACTIVE INGREDIENT | COMMON BRAND NAMES | USUAL ADULT RANGE | PROFILE |
|---|---|---|---|
| Ibuprofen | Advil, Motrin, Nurofen | 200-400 mg every 6-8 h (max 2.4 g/day) | Moderate GI; favorable CV at low doses |
| Naproxen sodium | Aleve, Naprosyn | 250-500 mg every 12 h (max 1 g/day) | Long half-life; best CV profile among NSAIDs |
| Ketoprofen | Orudis, Oruvail | 50-100 mg every 8-12 h PO; IM/IV in hospital | Potent anti-inflammatory |
| Ketorolac tromethamine | Toradol | 10 mg every 6 h PO; IM/IV in hospital (max 5 days) | Very potent; 5-DAY LIMIT (GI and renal risk) |
| Nimesulide | varies by country (not approved in US/UK/Canada) | 100 mg every 12 h (limit 15 days) | Hepatic risk; short-term use; restricted in some countries |
| Diclofenac sodium | Voltaren | 50 mg every 8-12 h; ER 75-150 mg once daily | High CV risk — avoid in cardiac patients |
| Diclofenac potassium | Cataflam, Voltaren Rapid | 50 mg every 8 h (faster onset of action) | Same CV profile as the sodium salt; faster onset |
| Meloxicam | Mobic | 7.5-15 mg once daily | COX-2 preferential; intermediate GI profile |
| Aceclofenac | varies by country | 100 mg every 12 h | Diclofenac analog; somewhat better GI profile |
| Piroxicam | Feldene | 10-20 mg once daily | Very long half-life; declining use due to GI/skin profile |
| Celecoxib | Celebrex | 200 mg once daily | Selective COX-2 inhibitor; better GI profile; CV similar to others |
| Etoricoxib | Arcoxia (not available in US) | 60-120 mg once daily | Selective COX-2 inhibitor; profile similar to celecoxib |
A practical caveat: patients commonly combine two different NSAIDs without knowing (a flu remedy with aspirin plus ibuprofen for muscle pain, for example) — a combination that does not raise efficacy but adds GI, CV, and renal toxicity. Asking explicitly about other meds before prescribing another NSAID is sound practice.
Dosing, interactions, and special populations
Older adults. GI, renal, and CV risk rises with age. In frail older adults I avoid chronic use whenever possible; when unavoidable, I add a PPI, choose the NSAID with the best CV profile, and monitor renal function and blood pressure. Topicals for superficial joints are useful.
Renal impairment. Contraindicated when clearance < 30 mL/min; caution at 30-60. The mechanism is inhibition of renal prostaglandins (loss of afferent arteriolar vasodilation) — an effect amplified by dehydration, ACEi/ARB and diuretic (the "triple whammy").
Heart failure. NSAIDs retain sodium/water and may decompensate HF. Contraindicated in NYHA IV and avoided in chronic use in cardiac patients. Diclofenac and etoricoxib have a higher CV signal; naproxen is the most conservative.
Pregnancy and lactation. Contraindicated in the third trimester (premature closure of the ductus arteriosus, oligohydramnios, prolongation of labor); the FDA (2020) recommends avoiding them from 20 weeks onward. Acetaminophen is first-line in pregnancy. During breastfeeding, ibuprofen and naproxen are the best options due to minimal milk excretion; celecoxib is acceptable.
Adverse effects, risks, and contraindications
In acute, brief use, most patients tolerate NSAIDs well. Trouble arises with prolonged use, vulnerable populations, and incautious combinations. The risk profile is dose- and time-dependent.
Other relevant effects: sodium and water retention (hypertension, edema, HF decompensation); bronchospasm in susceptible asthmatics (Samter's triad: asthma + nasal polyps + NSAID intolerance); hypersensitivity reactions (urticaria, angioedema, rarely anaphylaxis).
Strong contraindications: active peptic ulcer or recent GI bleeding; clearance < 30; HF NYHA IV; known hypersensitivity; pregnancy in the third trimester; active IBD (relative). In established coronary disease, chronic use is avoided — when needed, low-dose naproxen for the shortest possible time is the usual choice.
Limitations and what is still unknown
Even with extensive literature, gaps remain — and popular beliefs that do not survive a careful reading of the evidence. The most common is treating OTC NSAIDs as harmless for routine, continuous use.
Myth vs. Fact
OTC NSAIDs are "harmless" and can be used daily
Chronic NSAID use raises GI risk (bleeding), cardiovascular risk (MI, stroke), and renal risk (AKI). Even over-the-counter options carry a meaningful risk profile. For use beyond 7-10 days, especially in patients over 60 or with comorbidities, the right move is to reassess with a physician.
Evidence Gaps
Complex patients are underrepresented in trials. Older adults with OA frequently have HBP, DM, CKD, or coronary disease — criteria that exclude them from pivotal studies; in the real-world population, decisions rely on extrapolation and observational cohorts. The topical-vs-oral comparison at equivalent doses, which the topical analgesics article explores in depth, also has gaps in indications outside OA.
Within-class heterogeneity. Guidelines treat "NSAIDs" as a homogeneous block, but the CV risk gap between naproxen and diclofenac, or the hepatic gap between nimesulide and ibuprofen, is clinically meaningful. In chronic pain there is no consensus on a practical limit for continuous use — reassessing every 4-6 weeks and pursuing alternatives (exercise, medical acupuncture, antidepressants at analgesic doses) is the reasonable standard.
Relationship with medical acupuncture
Medical acupuncture is especially useful where NSAIDs show their greatest limitations: chronic pain. No pharmacologic interactions are described in the available literature, and the combination is considered safe; some patients report needing NSAIDs less often when acupuncture is integrated into the multimodal plan — any dose adjustment or reduction is the exclusive decision of the attending physician. Moderate evidence supports this benefit in chronic low back pain, migraine (prophylaxis), and knee osteoarthritis. The article Chronic NSAIDs vs Acupuncture compares the approaches side by side.
NSAIDS VS. MEDICAL ACUPUNCTURE
| ASPECT | NSAIDS | MEDICAL ACUPUNCTURE |
|---|---|---|
| Acute inflammatory pain | High | Low to moderate |
| Chronic OA (long-term management) | Moderate (risk limits use) | Moderate |
| Acute migraine | Moderate | Low (acute) / Moderate (prophylaxis) |
| Long-term use | Limited by risk profile | Generally tolerated, with rare adverse events |
| GI/CV/renal risk | Significant | Low (rare adverse events: local bruising, needling pain, rarely pneumothorax or syncope) |
| Described drug interactions | Frequent | None described in the available literature |
When to seek medical care
NSAIDs are useful in well-defined flares; prolonged use or use in vulnerable populations requires medical evaluation.
Frequently Asked Questions about NSAIDs
There is no "safest NSAID" in absolute terms — there is a safest NSAID for the specific patient. With high cardiovascular risk, naproxen tends to be more conservative. With high gastrointestinal risk (prior ulcer, anticoagulant), celecoxib with a PPI is usually the best choice. For occasional short-term use in a healthy adult, low-dose ibuprofen does the job. Diclofenac has a higher CV signal (avoid in cardiac patients); nimesulide has a hepatic signal and limited duration. The rational decision: assess the individual risk profile, choose the NSAID that minimizes the predominant risk, and use the lowest effective dose for the shortest possible time.
In patients at higher GI risk (prior ulcer, concomitant anticoagulant or corticosteroid, age over 65, prolonged use), NSAID + PPI is routine and significantly cuts GI complications — the standard in NICE and ACG guidelines. One caveat: the PPI protects against gastropathy but not against cardiovascular, renal, or hepatic risk. It covers one axis, not all of them. The decision to combine belongs to the physician, who weighs the overall risk profile and the expected duration.
Ibuprofen has a dose-dependent response up to a plateau. For mild-to-moderate pain in adults, 200-400 mg is usually effective; 600 mg adds modest relief but proportionally raises the risk of adverse effects. The practical rule is to start at the lowest effective dose and escalate only if needed — for many acute conditions, 400 mg suffices for 3-5 days. Combining ibuprofen with acetaminophen, in patients without contraindications, is a classic way to boost analgesia without raising the NSAID dose.
For localized pain in superficial joints (knee, hand, elbow) and focal musculoskeletal pain, topical NSAIDs have good evidence — clinically meaningful efficacy with much lower systemic exposure, and therefore a more favorable GI, CV, and renal risk profile. In knee and hand OA, recent guidelines (NICE, OARSI) prefer topical over oral NSAIDs. For deeper structures (spine, hip, visceral pain), the evidence is weaker and topicals do not replace oral therapy. In older adults or patients with comorbidities, a topical is usually the first try.
NSAIDs are contraindicated in the third trimester (premature closure of the ductus arteriosus, oligohydramnios, prolonged labor). The FDA (2020) recommends avoiding NSAIDs from 20 weeks onward. In the first and early second trimester, short-term use for a specific indication can be considered — but acetaminophen remains the first-line analgesic in pregnancy. If a pregnant patient is already on chronic NSAIDs (for a rheumatologic disease, for example), the decision is individualized and shared between the rheumatologist and the obstetrician. Self-medication with NSAIDs during pregnancy is discouraged at any stage.
Related Reading
Deepen your knowledge with related articles